Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy and safety of pola-based therapy in molecularly defined high-risk DLBCL: A retrospective analysis of real-world data

View Full Paper
Ask AI
Bookmark
Share

Authors

XWXin WangJCJianbin ChenLLLin Liu

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows high response rates in high-risk DLBCL patients treated with pola-based regimens, indicating favorable efficacy and safety profiles.

Key Points

  • Complete response rate among evaluable patients reached 64.7%, indicating effective treatments.
  • Among 40 DLBCL patients, adverse events included gastrointestinal reactions in 60% and neutropenia in 5%.
  • Observational analysis assessed efficacy and safety of Pola-based regimens in high-risk DLBCL patients with varying responses.
  • Findings support precision treatment strategies, though further validation in larger cohorts is necessary.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e5e3https://doi.org/10.1182/blood-2025-8083
View Full Paper
Ask AI
Bookmark
Share